Case Study:
Finding Ultra Rare Disease Patients with AI Using Claims and EHR Data
Ultra Rare Disease Patient Identification Using AI with Claims and EHR Data
Ultra rare disease patients are notoriously difficult to find due to the fact that they are ultra rare.
The Client Problem
Finding patients with a specific ultra rare disease was difficult for the client. They did all the usual approaches of educating every physician who may come into contact with a patient of this type but this was costing significantly and yielding little return.
The Solution
The team turned to Eularis for Artificial Intelligence Powered Analytics to help. We were given access to claims databases that the client had purchased. We began by identifying the patient journey of the few patients who had been diagnosed, and from that, we were able to understand the specifics of the tests and medical journey of those patients. We then also accessed EHR data that we have the ability to source from over 30 countries and used that to then identify other patients with similar early-stage symptoms with a high probability of having the condition.
The Outcome
29 previously undiagnosed patients were able to get confirmed diagnoses and appropriate treatment early in their disease progression which led to an improved clinical outcome for them and a significant financial return for the client. Considered the ultra-rare condition, this was an extremely high number of additional patients resulting in hundreds of millions of additional revenue for the lifetime of these patients.
To achieve these kinds of results, contact Eularis today.
Latest Blogs
Check out our latest blogs
We’re Doing AI” Is Not a Board Answer
There is a moment I have seen play out in pharmaceutical boardrooms again and again. It usually comes in the second half of the agenda,
Why Most AI Governance Frameworks Are the Wrong Fit for Pharma
Most pharmaceutical organizations now have some form of AI governance. On paper, that sounds reassuring. In practice, it often means a policy document, a review
Why Most Pharma AI Strategies Fail the CFO Test
Most pharmaceutical organizations do not struggle to explain what their AI programmes do. They struggle to explain, in financial terms, why those programmes deserve sustained